Original insights, commentary, and expert analysis
In the constantly evolving world of the biopharma industry, staying abreast of the latest news and developments is essential for
Eli Lilly, a key player in the biopharmaceutical sector, has made headlines with its recent decision to discontinue the development
In a substantial move set to bolster the biotech manufacturing landscape, National Resilience has secured $825 million in debt financing
In a groundbreaking development for the biopharma industry, Sonoma Biotherapeutics has unveiled early data showcasing the effectiveness of its innovative
The biopharmaceutical industry is continually evolving, with innovative therapies emerging to transform the landscape of disease treatment. One significant advancement
In the rapidly advancing field of biopharma, novel therapies such as CRISPR gene editing hold great promise for treating various
The pharmaceutical industry is at a transformative juncture, underscored by the latest developments highlighted in here at Medicine to Market.
In a striking turn of events, Ventyx Biosciences witnessed its shares skyrocket by nearly 100% following promising results from a
The recent announcement by Merck KGaA regarding the closure of its Arklow API production facility has raised eyebrows within the
In recent developments within the biopharma landscape, Ventyx Biosciences has captured the attention of investors and healthcare professionals alike as
In a significant move to alleviate the financial burden of diabetes management, California Governor Gavin Newsom has launched an affordable
AstraZeneca’s recent commitment of billions of dollars to establish a cutting-edge active pharmaceutical ingredient (API) facility in Albemarle County, Virginia
The anticipation surrounding the Centers for Medicare and Medicaid Services (CMS) announcement regarding coverage for GLP-1 weight loss drugs for